Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday morning.

Several other research firms have also issued reports on TEVA. Barclays assumed coverage on Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 target price for the company. UBS Group upped their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Bank of America raised their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Finally, Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, December 22nd. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $33.67.

Teva Pharmaceutical Industries Trading Up 2.5%

Shares of Teva Pharmaceutical Industries stock opened at $32.80 on Friday. The company has a market capitalization of $37.62 billion, a P/E ratio of 54.67, a price-to-earnings-growth ratio of 1.86 and a beta of 0.66. The stock has a fifty day simple moving average of $28.28 and a 200 day simple moving average of $21.71. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $33.42. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 12,300 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total transaction of $371,460.00. Following the sale, the chief accounting officer owned 5,650 shares of the company’s stock, valued at $170,630. The trade was a 68.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Richard Daniell sold 115,468 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president directly owned 48,384 shares of the company’s stock, valued at $1,387,653.12. The trade was a 70.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 622,060 shares of company stock valued at $17,076,965 in the last quarter. Corporate insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bourgeon Capital Management LLC lifted its stake in Teva Pharmaceutical Industries by 100.7% in the second quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company’s stock worth $12,134,000 after acquiring an additional 363,252 shares during the period. IFM Investors Pty Ltd increased its position in Teva Pharmaceutical Industries by 9.4% during the 2nd quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock valued at $3,797,000 after purchasing an additional 19,447 shares during the period. Vontobel Holding Ltd. raised its holdings in Teva Pharmaceutical Industries by 5.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 719,676 shares of the company’s stock worth $12,062,000 after purchasing an additional 37,455 shares in the last quarter. Oak Harvest Investment Services purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $1,010,000. Finally, Swiss National Bank boosted its stake in shares of Teva Pharmaceutical Industries by 15.5% during the 2nd quarter. Swiss National Bank now owns 3,616,500 shares of the company’s stock valued at $60,613,000 after purchasing an additional 486,100 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva struck a funding agreement with Royalty Pharma for up to $500M to accelerate clinical development of TEV‑’408 for vitiligo; Teva retains global commercial rights and expects to share trial results in 2026. This de‑risking funding and preserved commercial upside likely drove optimism. Article Title
• Positive Sentiment: Management issued FY‑2025 EPS and revenue guidance (EPS 2.55–2.65; revenue $16.8–17.0B) and reiterated multi‑year targets, which investors interpreted as bullish for future growth and helped lift sentiment. Coverage highlighting that optimism also supported the rally. Article Title
• Neutral Sentiment: Teva will present at the 44th Annual J.P. Morgan Healthcare Conference (Jan 13); the presentation could provide more detail on commercial strategy and pipeline timelines but is informational until new disclosures are made. Article Title
• Neutral Sentiment: Positive analyst/commentary pieces (Zacks, Yahoo) highlight TEVA as a value/turnaround name with high institutional ownership — supportive background but not a near‑term catalyst by itself. Article Title

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.